Kringle Pharma,Inc. Logo

Kringle Pharma,Inc.

Develops regenerative HGF medicines for rare and intractable neurological diseases.

4884 | T

Overview

Corporate Details

ISIN(s):
JP3270790003
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号彩都バイオインキュベータ207号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on the research and development of regenerative medicines for intractable diseases. Originating as a university spin-off, the company's core strength is its proprietary platform for manufacturing pharmaceutical-grade recombinant human Hepatocyte Growth Factor (HGF). HGF is an endogenous protein with protective, regenerative, and tissue-repairing functions. Kringle Pharma is advancing its HGF drug candidates through clinical trials for several conditions, including rare and neurological diseases such as spinal cord injury and Amyotrophic Lateral Sclerosis (ALS).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-16 09:00
Registration Form
有価証券届出書(組込方式)
Japanese 364.6 KB
2025-05-12 08:41
Report Publication Announcement
確認書
Japanese 8.2 KB
2025-05-12 08:40
Interim Report
半期報告書-第24期(2024/10/01-2025/09/30)
Japanese 181.3 KB
2024-12-23 06:32
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB
2024-12-23 06:31
Registration Form
確認書
Japanese 8.2 KB
2024-12-23 06:30
Annual Report
有価証券報告書-第23期(2023/10/01-2024/09/30)
Japanese 2.2 MB
2024-12-23 06:30
Governance Information
内部統制報告書-第23期(2023/10/01-2024/09/30)
Japanese 21.7 KB
2024-08-26 03:25
Post-Annual General Meeting Information
臨時報告書
Japanese 22.4 KB
2024-05-13 08:40
Quarterly Report
四半期報告書-第23期第2四半期(2024/01/01-2024/03/31)
Japanese 179.6 KB
2024-05-13 08:40
Report Publication Announcement
確認書
Japanese 8.2 KB
2024-02-09 07:41
Report Publication Announcement
確認書
Japanese 8.2 KB
2024-02-09 07:40
Quarterly Report
四半期報告書-第23期第1四半期(2023/10/01-2023/12/31)
Japanese 139.3 KB
2023-12-25 08:24
Post-Annual General Meeting Information
臨時報告書
Japanese 22.3 KB
2023-12-25 08:23
Registration Form
確認書
Japanese 8.2 KB
2023-12-25 08:22
Governance Information
内部統制報告書-第22期(2022/10/01-2023/09/30)
Japanese 21.6 KB

Automate Your Workflow. Get a real-time feed of all Kringle Pharma,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kringle Pharma,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kringle Pharma,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN
IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX

Talk to a Data Expert

Have a question? We'll get back to you promptly.